文献速递淋巴瘤

苯达莫司汀联合利妥昔单抗治疗具有肾脏意义的惰性B细胞淋巴瘤

Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance.
PubMed 文献 · Am J Hematol · 2017-12-06

这项前瞻性单中心研究纳入20例具有肾脏意义的惰性B细胞非霍奇金淋巴瘤患者,采用不含类固醇的利妥昔单抗联合苯达莫司汀方案,17例(85%)达完全或部分血液学缓解,肾小球病变和肾小管间质病变患者均观察到肾脏缓解,12个月死亡率为10%,方案总体耐受良好。

要点

  • 17例(85%)达完全或部分血液学缓解,其中完全缓解12例、部分缓解5例。
  • 肾小球病变患者9/12例(75%)达完全或部分肾脏缓解,肾小管间质病变患者6/8例(75%)达肾脏缓解。
  • 12个月死亡率为10%,方案总体耐受良好。

核心结论

  • 尽管就诊时存在严重肾脏疾病、20%患者为复发性惰性B细胞非霍奇金淋巴瘤且合并多种合并症,利妥昔单抗联合苯达莫司汀方案在本系列中有效且安全。
  • 作者认为该方案应作为具有肾脏意义的惰性B细胞非霍奇金淋巴瘤患者一线治疗的进一步评估方向。

研究设计与样本

  • 前瞻性单中心研究,纳入20例具有肾脏意义的惰性B细胞非霍奇金淋巴瘤患者,其中肾小管间质表现8例、伴或不伴单克隆免疫球蛋白沉积的肾小球病变12例。
  • 患者接受不含类固醇的利妥昔单抗联合苯达莫司汀方案,无或少于1个月类固醇摄入,80%为一线治疗。

主要发现

  • 17例(85%)达完全血液学缓解(12例)或部分血液学缓解(5例)。
  • 12例惰性B细胞非霍奇金淋巴瘤相关肾小球病变患者中9例(75%)达完全或部分肾脏缓解。
  • 肾小球病变且达完全血液学缓解的6例患者中5例(83%)达完全肾脏缓解,未达完全血液学缓解的6例中1例(17%)达完全肾脏缓解。
  • eGFR从38升至58 mL/min/1.73 m2,5例患者恢复至基线水平。
  • 肾小管间质表现8例中6例(75%)达肾脏缓解(5例完全肾脏缓解),eGFR从29升至48 mL/min/1.73 m2。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment of indolent B-cell non-Hodgkin lymphomas (iNHL) of renal significance is challenging given the need for deep and prolonged hematological response to restore and control renal function overtime, yet to be balanced with the risk of adverse drug-related events. This prospective single-center study included 20 patients with iNHL of renal significance (tubulointerstitial presentation [n = 8], glomerulopathy with or without monoclonal Ig deposits [n = 12]) who received a steroid-sparing regimen of rituximab plus bendamustine (BR), with either no or <1 month of steroid intake (as a first line therapy in 80%). Seventeen patients (85%) achieved a complete (CHR, n = 12) or a partial (PHR, n = 5) hematological response. Nine out of the 12 patients (75%) with iNHL-related glomerulopathy had a complete (CRR) or a partial (PRR) renal response. Among the six patients with glomerulopathy and CHR, five had a CRR (83%) compared to 1/6 (17%) that did not reach CHR. eGFR increased from 38 to 58 mL/min/1.73 m2 , and returned to baseline in five patients. Among the eight patients with a tubulointerstitial presentation, six (75%) had a renal response (5 CRR), and eGFR increased from 29 to 48 mL/min/1.73 m2 . One patient with a PHR had a renal relapse. Mortality rate was 10% at 12 months. The BR regimen was well tolerated overall. Thus, despite severe renal disease at presentation, a relapsing iNHL in 20% of patients and several comorbidities, the BR regimen was efficient and safe in our series. It should be further assessed as a first line therapy for patients with iNHL of renal significance.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Ribes D, Hachem HEL, Oberic L, et al. Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance. Am J Hematol. 2017. PMID: 29168251. doi:10.1002/ajh.24984

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。